We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




First Saliva Diagnostic Test for Endometriosis Delivers Reliable Results Within Days

By LabMedica International staff writers
Posted on 12 Feb 2025

Endometriosis affects approximately 1 in 10 women globally, with a range of symptoms that can severely impact their health, quality of life, and fertility. More...

The delay in diagnosis, which can take between 7 to 10 years, is a significant barrier to improving care, life quality, and fertility outcomes. Now, a pioneering saliva-based diagnostic test for endometriosis offers new possibilities for early and non-invasive diagnosis of this painful disease.

The Ziwig Endotest, developed by Ziwig (Lyon, France), is a saliva test for endometriosis that provides a reliable diagnosis within just a few days. Ziwig is transforming the diagnosis and treatment of women's health conditions by harnessing the power of salivary RNA. The Ziwig Endotest is the first-ever application of salivary microRNA1-6 in gynecology. This test requires only a simple saliva sample, with the diagnosis performed in the laboratory. It is based on high-throughput sequencing of the microRNA found in saliva, combined with artificial intelligence (AI) to process the large volumes of data generated. Using the Ziwig Endotest, a diagnosis can be made in just a few days with exceptional accuracy (97.4% sensitivity, 93.7% specificity). The test enables clinicians to reliably confirm or exclude a diagnosis of endometriosis and distinguish it from other conditions with similar symptoms. It is particularly useful in complex cases where medical imaging may be inconclusive.

Ziwig’s non-invasive approach to saliva sampling, along with technological advancements in sequencing and AI, makes accurate, early diagnosis of endometriosis more accessible. The company’s focus on the RNA and extracellular vesicles in saliva represents a milestone in personalized medicine. The Ziwig Endotest offers a breakthrough biological test for healthcare providers and patients by reducing diagnostic delays, identifying complex and early-stage cases sooner, providing an alternative to invasive procedures, and enhancing fertility preservation through earlier diagnosis.

"With Ziwig Endotest we are determined to end the unacceptable diagnostic wandering that leaves many women in pain,” said Yahya El Mir, Ziwig CEO-Founder.

Related Links:
Ziwig


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.